Biomerica's Fortel Test Gains Approval, Expanding Global Reach
Biomerica's Groundbreaking Test Approved in UAE for Early Kidney Detection
Biomerica, Inc. (NASDAQ: BMRA), a frontrunner in advanced diagnostic solutions, has achieved a significant milestone with the approval of its Fortel Kidney Disease Test by the United Arab Emirates (UAE) Ministry of Health and Prevention. This groundbreaking test is now poised to make a considerable impact in a region grappling with the pressing issue of chronic kidney disease (CKD).
Innovative Testing for Quick Results
The Fortel Kidney Disease Test stands out for its simplicity and efficiency. Designed to deliver results in a mere 10 minutes using just a urine sample, this innovative tool identifies low levels of microalbumin—an essential early marker for kidney damage. Given that individuals with diabetes, high blood pressure, obesity, and those above 65 years are at heightened risk, frequent testing becomes crucial. Alarmingly, CKD remains largely underdiagnosed, with over 80% of those at risk unaware of their condition. The increasing prevalence of CKD poses significant health risks, including heightened vulnerability to heart disease and stroke, making early detection pivotal.
Targeting Key Risk Factors
In the UAE, conditions like diabetes and hypertension predominantly contribute to CKD, as reported by the International Diabetes Federation. Shockingly, over 12% of the adult population suffers from diabetes, while studies estimate hypertension affects 29% to 35% of residents. Such statistics highlight the urgency of early screening, particularly since CKD often manifests without symptoms until it reaches an advanced stage. As CKD is frequently dubbed a “silent disease,” prompt detection through tools like the Fortel Test is essential for initiating early intervention.
Zack Irani, CEO of Biomerica, emphasized the significance of the Fortel Test in preventative healthcare: "The Fortel Kidney Disease Test addresses a critical need in preventative healthcare by allowing the possible detection of kidney disease before symptoms appear. With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed.”
Broadening Access to Healthcare Solutions
This approval marks a pivotal moment in Biomerica’s increasing influence in the Middle East, building on the success of its EZ Detect Colon Disease Test and other diagnostic advancements. The company is proactively forming partnerships with reputable distributors and healthcare providers within the UAE, ensuring that the Fortel Kidney Disease Test will be widely accessible throughout the region.
Commitment to Improving Patient Outcomes
Biomerica is steadfast in its commitment to providing affordable, high-quality diagnostics that empower both patients and healthcare professionals. The Fortel Test is part of a broader portfolio designed to enhance patient outcomes through early detection and tailored treatment strategies.
About Biomerica
Biomerica, Inc. is at the forefront of biomedical technology, focused on developing advanced diagnostic and therapeutic products for the point-of-care and clinical laboratory markets. Their innovations aim to improve health and well-being while also reducing healthcare costs. With a concentrated effort on illnesses related to gastrointestinal and inflammatory conditions, Biomerica has several products in various stages of development.
Frequently Asked Questions
What is the Fortel Kidney Disease Test?
The Fortel Kidney Disease Test is a rapid diagnostic tool that detects early signs of kidney damage through urine analysis, providing results in just 10 minutes.
What are the major risk factors for CKD in the UAE?
The principal risk factors for chronic kidney disease in the UAE include diabetes, hypertension, obesity, and advanced age.
How does early detection of CKD benefit patients?
Early detection allows for timely intervention which can slow disease progression, and potentially reduce the need for dialysis or kidney transplants.
What partnerships has Biomerica established in the UAE?
Biomerica is collaborating with leading distributors and healthcare providers in the UAE to enhance the accessibility of the Fortel Kidney Disease Test across the region.
What goals does Biomerica aim to achieve with this test?
Biomerica aims to enhance early detection and preventative care for kidney disease, ultimately improving health outcomes and reducing healthcare costs.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
